A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers.
about
A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
A Phase 1 open-label study to ...... reast and gynecologic cancers.
@en
A Phase 1 open-label study to ...... reast and gynecologic cancers.
@nl
type
label
A Phase 1 open-label study to ...... reast and gynecologic cancers.
@en
A Phase 1 open-label study to ...... reast and gynecologic cancers.
@nl
prefLabel
A Phase 1 open-label study to ...... reast and gynecologic cancers.
@en
A Phase 1 open-label study to ...... reast and gynecologic cancers.
@nl
P2093
P50
P1476
A Phase I Open-Label Study to ...... Breast and Gynecologic Cancers
@en
P2093
Andrew Foxley
Barry R Davies
Benoit You
Claire Corcoran
Elza C de Bruin
Emma J Dean
Gaia Schiavon
Gerald Batist
Helen Ambrose
J Carl Barrett
P304
P356
10.1158/1078-0432.CCR-17-2260
P407
P577
2017-10-24T00:00:00Z